Advanced Imaging and AI in Drug Development: Autoimmunity
Join Dr. Olga Kubassova’s live webinar “Advanced Imaging and AI for Clinical Drug Development: Autoimmunity” to discuss the role of medical imaging markers and AI in drug development for auto-immune diseases. The session will begin with Dr. Kubassova’s talk followed by the live Q&A with the audience.
Key Discussion Points:
- The connection between the development of novel therapeutics and data sciences.
- The practical use of imaging in clinical trials: patient stratification and drug efficacy.
- Modern trial infrastructure to enable global reach and use of AI.
Date and Time:
Tuesday 7th April 2020, 11:00-12:00 am ET (16:00-17:00 GMT)
About the Webinar:
To succed in drug development, we need clear understanding of the disease biology and objective efficacy assessment for a novel treatment.
Imaging based endpoints support our understanding of the early treatment response and can predict trial outcomes. Optimal use of medical imaging has become critical to the modern trial designs and plays an essential role in de-risking R&D process and biotech investment.
AI-enabled methods for patient stratification and drug efficacy assessment can focus budgets and resources.
Advanced imaging, AI and global set-up of a trial demand modern infrastructure that is compliant with regulatory requirements but agile and fit for purpose of the trial. In the webinar, we will discuss the use of a cloud platform in trial settings.
With Covid-19 impact, we should prepare making treatment efficacy decisions with much smaller number of patients. Thus, better infrastructure and richer data will become the key drivers of successful trial outcome.
About Dr. Olga Kubassova:
Dr. Olga Kubassova, CEO of IAG, Image Analysis Group. She is a mathematician, computer scientist and entrepreneur, playing a significant role in the development and use of medical imaging in clinical research and diagnosis. She is an active researcher, scientific adviser to the UK government and EU funding bodies, inc. European Commission, Innovative Medicines Initiative. She is an editor and reviewer of several scientific journals. She is also a founding member of “The 2% Club” to support women in leadership positions, a fellow of the Royal Society of Medicine, Royal Society of Engineering, 4-time winner of the national and international “Entrepreneur of the Year” award.
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com
The World Molecular Imaging Society is an international scientific-educational organization dedicated to the understanding of biology and medicine through multimodal in vivo imaging of cellular and molecular events involved in normal and pathologic processes and utilization of quantitative molecular imaging in patient care.
Questions or need held registering, please email <eden.chrifi-alaoui @ ia-grp.com>